Navigation Links
Risk of stroke doubles if diagnosed with Type 2 diabetes

Individuals diagnosed with Type 2 diabetes are at double the risk of having a stroke compared to those without diabetes, according to new research from the University of Alberta. It was found that the risk of a stroke is considered high within the first five years of treatment for Type 2 diabetes and more than doubles the rate of occurrence.

For this study, the researchers entered 12,272 subjects into a Type 2 diabetes cohort. All subjects were recently diagnosed with Type 2 diabetes and had a mean age of 64 years. After five years of monitoring, stroke incidence rates were compared between the cohort and the general population.

“What we found is that 9.1 per cent of the diabetes cohort had a stroke within the first five years of their diagnosis,” Dr. Thomas Jeerakathil, an assistant professor in neurology, at the University of Alberta. “We also found that compared to persons from the general population of a similar age, the relative risk for stroke was much greater in younger persons with diabetes than for older persons.

As it has been more common to study stroke prevalence within 10 years after diagnosis, this is the first study to specifically examine stroke-related outcomes immediately after the diagnosis of and initiation of treatment for Type 2 diabetes.

Jeerakathil indicates it is possible that physicians are undertreating stroke risks because of a prevailing attitude among physicians and patients that the cardiovascular complications of diabetes occur long after diagnosis rather than in the first five years.

“We hope our findings will help to dispel the notion that the risk of stroke occurs only in the long term and will improve the motivation of both patients and health care providers to aggressively control cardiovascular risk factors soon after diagnosis.” said Jeerakathil.


'"/>

Source:University of Alberta


Page: 1

Related biology news :

1. Researchers discover molecule that causes secondary stroke
2. Molecular cabal contributes to stroke damage
3. Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke
4. Limiting the damage in stroke
5. Cord blood cells may widen treatment window for stroke
6. Bad enzymes may wear white hats after stroke
7. Stem cell transplants improve recovery in animal models for stroke, cerebral palsy
8. Internal body clock dictates timing of different types of stroke
9. New compound reduces stroke damage
10. Acidity in the brain could hold the key to stroke treatment
11. UBC researchers find stroke death channel
Post Your Comments:
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Acculturation affects smoking cessation success among Latinos 2Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 1Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 1NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 8New Clues to How Fish Oils Help Arthritis Patients 60263 1New Clues to How Fish Oils Help Arthritis Patients 60263 2
...s, are often updated publicly as their analytical ...e Journal of Molecular Diagnostics, NIH grantees r... on a silicon chip" called the MitoChip v2.0 that ...all mitochondrial DNA. Mitochondria, the energy-p...ue because they are equipped with their own geneti...
...h carrots, green beans, red peppers and broccoli a... researchers say. , Dr. N. Joy Dubost, who recentl...te, measured the activity of two antioxidants, pol...using the ORAC assay and HPLC instrumentation, as ...portabella mushrooms had an ORAC value of 9.7 micr...
...ways show it, but people are rarely born with two ...d legs to grow in the right places and point in th...es between our fingers and toes and every other fo...aking, the genetic instructions used to construct ...han half a billion years ago in fishes, not along ...
Other Biology News:Mitochondrial DNA sequencing tool updated 2Mitochondrial DNA sequencing tool updated 3Mitochondrial DNA sequencing tool updated 4Mushrooms as good an antioxidant source as more colorful veggies 2UF scientists discover evolutionary origin of fins, limbs 2UF scientists discover evolutionary origin of fins, limbs 3
(Date:12/3/2009)MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator of advanced optical instruments, announced today that it has signed a licensing agreement with Harvard University granting Nikon the rights to u
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
...all/ - YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ...velops and commercializes differentiated products ... completed accrual in the first 50-patient,cohort ...n with irinotecan,for the treatment of colorectal ... consistent with data from previous trials of nimo...
...eutics, Inc.,a biopharmaceutical company developin... announced the appointment of Colin Reisner, MD, F...r and Executive Vice,President of Clinical Develop...e position of Vice President, Regulatory Affairs a...nd Michael as we continue to build,our team with e...
..., a privately,held orthobiologic company, announce...e Finance Forum in San Francisco, CA from January ... CEO of ISTO, will present on,Tuesday, January 8th...ake,Hotel at 450 Powell St. Information about the ...www.onemedplace.com ., ISTO,s rich product pipeli...
Other Biology Technology:YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 3Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 2Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 3
...oduced by a patented microwave process which makes..., even cell attachment, increased cell growth and ...th uunder difficult conditions, including reduced ...ovide a more ecominic alternative to expensive and...
...es are designed for quick and easy protein purific...re two 0.25mm holes laser cut at the conical ends ... incubation of the gel matrix with buffer, during ...the buffer. Following a centrifugation step, the p...
...-art in permanent mounting media. It is designed f...al organic insoluble substrates such as diaminoben... organic solvent compatible chromogen substrates o...y and cytology applications using manual and autom...
...ndustry's first siRNA sequence design software in ...ls consistent with new experimental strategies and... With the introduction of our new, enhanced, and e...to offer the most significant advancement in RNAi ...
Biology Products: